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processes is generally considered less attractive to improve patient
outcomes. Nevertheless, it might result in better patient outcomes,
without further increasing costs. Because early initiation of treat-
ment is of vital importance for patients with head and neck cancer
(HNC), these care processes were redesigned. Objectives: This
study aimed to assess patient outcomes and cost-effectiveness of
this redesign. Methods: An economic (Markov) model was con-
structed to evaluate the biopsy process of suspicious lesion under
local instead of general anesthesia, and combining computed
tomography and positron emission tomography for diagnostics
and radiotherapy planning. Patients treated for HNC were included
in the model stratiﬁed by disease location (larynx, oropharynx,
hypopharynx, and oral cavity) and stage (I–II and III–IV). Probabil-
istic sensitivity analyses were performed. Results: Waiting time
before treatment start reduced from 5 to 22 days for the included
patient groups, resulting in 0.13 to 0.66 additional quality-adjustedee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.04.003
imons@maastro.nl.
ndence to: Pascale A.M. Simons, MAASTRO Clinic,life-years. The new workﬂow was cost-effective for all the included
patient groups, using a ceiling ratio of €80,000 or €20,000. For
patients treated for tumors located at the larynx and oral cavity,
the new workﬂow resulted in additional quality-adjusted life-
years, and costs decreased compared with the regular workﬂow.
The health care payer beneﬁted €14.1 million and €91.5 million,
respectively, when individual net monetary beneﬁts were extrapo-
lated to an organizational level and a national level. Conclusions:
The redesigned care process reduced the waiting time for the
treatment of patients with HNC and proved cost-effective. Because
care improved, implementation on a wider scale should be
considered.
Keywords: cost-effectiveness analysis, economic evaluation, head and
neck, process redesign, waiting time.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Optimal treatment for every individual patient has always been
the main goal in medicine. However, the increased number of
costly new treatment options combined with the aging popula-
tion result in a dramatic increase in health care costs [1,2].
Because resources are scarce, decisions have to be made on
which treatment options should be made available for society
and included in health care insurance packages. Cost-
effectiveness analyses can support these difﬁcult decisions by
providing the relevant information including long-term costs and
beneﬁts for patients and the health care sector [3].
A redesign intervention of care processes might optimize
quality and efﬁciency of care, although medical professionals
often consider it less attractive than adopting new technologies.
Time to treatment or waiting time might be shortened, resulting
in better patient outcomes without driving costs to a maximum.For oncology patients in general, and for patients with head and
neck cancer (HNC) in particular, waiting time is signiﬁcantly
associated with patient outcome. Because HNC tumors have a
fast doubling time, long waiting times cause tumor progression
and negatively affect local tumor control and survival rates [4].
Based on theoretical evidence, delay in radiotherapy (treatment
with irradiation) may affect the outcomes of treatment by
permitting the proliferation of clonogenic cells, leading to
decreased probabilities of local control, which has been con-
ﬁrmed by retrospective observational studies [5]. Chen et al. [4]
showed in a systematic review that the risk of local recurrence
(relative risk [RR] 1.15 per month waiting time) and mortality (RR
1.16 per month waiting time) increased for patients with HNC
with increased waiting time for radiotherapy. Waaijer et al. [6]
estimated an average control loss of 16% to 19% due to tumor
progression for a mean waiting time of 56 days, potentially
resulting in increased mortality [7]. The probability and severityociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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volumes have to be irradiated, causing a potential decrease in
quality of life for patients [8]. Therefore, optimization of care
processes to minimize the waiting time is important to improve
outcomes for patients with HNC.
The treatment of patients with HNC needs optimal collabo-
ration between several disciplines (head and neck [HN] surgeons,
radiation oncologists, medical oncologists, pathologists, radiol-
ogists, etc.) to improve medical decision making. Involving all
these disciplines could hamper short waiting times. With an aim
to optimize waiting times, we redesigned the care process and
evaluated its beneﬁts in terms of patient outcome and cost-
effectiveness.Methods
Markov Model Description
A cost-effectiveness analysis was performed for patients with
stage I and II and stage III and IV HNC located in the oropharynx,
larynx, hypopharynx, and/or oral cavity, for which the workﬂow
was redesigned. Patients were treated at the Maastricht Univer-
sity Medical Centre and at the MAASTRO CLINIC, in the joint
Multidisciplinary Head and Neck Board, including HN surgeons as
well as radiation oncologists. These particular patient groups
were considered because of the expected beneﬁts on patient
outcomes from a shortened time to treatment [4] and the
possibilities of redesigning the workﬂow for these patients in
particular. Results were stratiﬁed for tumor sites and stages
because differences in not only improvements in the waiting
time, but also the prognoses and quality of life of these patients
groups were expected. The Tumor Nodes Metastases stage group-
ing system of the Union for International Cancer Control, seventh
edition, was used for staging [9]. Stage IV can be further sub-
divided into stage IVa (based on T4 status), IVb (based on N3
status), and IVc (based on M1, distant metastases). In this study,
patients only with locoregional disease, that is, stage I, II, III, IVa,
and IVb, were included. Patients with stage IVc (metastasized
disease) were excluded.
In the studied organizations, the standard diagnostics of the
mentioned patient groups included a computed tomogram or
magnetic resonance imaging, an X-thorax, and a tumor biopsy
under full anesthesia in an operating theater in accordance with
the national guidelines for clinical practice [10]. For patients with
HNC treated by radiotherapy, a therapeutic computed
tomography-positron emission tomography (PET-CT) is per-
formed for treatment planning. In the regular workﬂow, this
PET-CT is performed after diagnosis within the preparation phase
of radiotherapy. To reduce waiting times and use equipment and
personnel more efﬁciently, the workﬂow of the diagnostic and
preparation phases of radiotherapy was redesigned. A Markov
model was used to analyze costs and beneﬁts of this logistic
process redesign. This redesign included two main organizational
changes:1. Performing a diagnostic tumor biopsy and evaluation of the
upper aerogastrointestinal tract under local instead of general
anesthesia (time to treatment shortened by 17 days).2. Performing a diagnostic PET-CT in radiation treatment posi-
tion using an immobilization mask before radiotherapy
instead of an additional PET-CT during preparation for radio-
therapy (time to treatment shortened by 5 days).
The rationale for the ﬁrst change was that the examination
under general anesthesia required available time in the operation
theater and this proved to be a rate-limiting step in the diagnosticprocess of patients with HNC. To increase the efﬁciency of the
diagnostic process and decrease waiting times for patients, new
methods were evaluated to diagnose HNC without losing the
quality of investigation. Chip-on tip cameras provide excellent
imaging and are technologically advanced as compared with ear-
lier ﬁber optic tools [11]. Imaging of the lungs has improved
drastically, and is increasingly performed under local anesthesia
since the development of these chip-on tip cameras. Because of
these positive results combined with the possibility of performing a
tumor biopsy under local instead of full anesthesia, a pilot was
performed for patients with HNC. Preliminary results from this
study show that ﬂexible pan endoscopy under local anesthesia is
as good as pan endoscopy under general anesthesia, and in
some situations superior, for example, assessment of larynx move-
ments. Although the accuracy of this diagnostic tumor biopsy
for HNC using local anesthesia is promising, it is still under
consideration.
The rationale for the second change was that staging PET-CT
is not standard in the diagnostics of patients with HNC. Usually,
locoregional staging is performed by CT and/or magnetic reso-
nance imaging of the HN region in accordance with the national
guidelines for clinical practice [10]. Screening for distant meta-
stases is usually done by a conventional chest X-ray (for low-risk
patients), or a CT-chest for high-risk patients. PET-CT in treat-
ment position of the HN and the upper thoracic area is not
performed in every radiotherapy center for radiation treatment
planning of HN tumors. An increasing number of radiotherapy
centers (including the studied organization), however, consider
PET-CT a standard procedure for treatment planning to facilitate
the delineation of the gross tumor volume for particular patient
groups [12,13]. Because of the etiological factors associated with
HNC (i.e., nicotine and alcohol abuse), these patients are also at
risk of secondary tumors, for example, lung cancer and/or
esophageal cancer. Performing a PET-CT for radiation treatment
planning, therefore, increases the detection of second primary
tumors and/or metastases that had not been identiﬁed in con-
ventional staging. This would lead to additional investigational
procedures and delay the start of treatment. By performing a
diagnostic PET-CT of the HN area and the chest in radiation
treatment position instead of performing a PET-CT after diag-
nosis, optimal staging, including screening for second primaries,
or metastases, is combined with the preparation for state-of-the-
art radiation treatment planning. By including a PET-CT in
radiation treatment position in the diagnostic process of patients
expected to receive radiotherapy treatment, time to treatment
can be reduced and a diagnostic CT becomes unnecessary.
The original/regular process ﬂow (regular workﬂow [RWF])
was compared with three new process ﬂows (new workﬂow
[NWF]): 1) tumor biopsy (to deﬁne tumor status) under local
anesthesia. Because local anesthesia can be provided outside of
operation theater, scheduling is independent of surgery sched-
ules and delays; 2) a diagnostic PET-CT used before radiotherapy;
and 3) a combination of 1) and 2) (see Table 1). Because only the
logistics of the workﬂow changed, the actual care/treatment of
the included patients did not, and was still in accordance with
the national guidelines for clinical practice [10]. Only patients
with tumors located in the larynx and in the oral cavity were
considered for a biopsy under local anesthesia, because the other
tumors cannot be optimally assessed under local anesthesia
because palpation forms a big part of this assessment. Most
patients with tumors of the oral cavity are treated with surgery as
primary treatment. Postoperative radiation therapy is given on
the basis of indications derived from the pathology report.
Therefore, these patients were not considered for a PET-CT in
radiation treatment position.
The current Markov model used in this study included four
health states: progression-free survival, local/regional recurrence
Table 1 – The gained working days due to the new workﬂow relative to the regular workﬂow.
Tumor site Stage Local
anesthesia
Diagnostic
PET-CT
Gained waiting
time (d)* (expected)
Beta PERT distribution
Minimum Maximum
Larynx I–II Yes Yes 22 10 38
III–IV Yes Yes 22 10 38
Oropharynx I–II No Yes 5 3 10
III–IV No Yes 5 3 10
Hypopharynx I–II No Yes 5 3 10
III–IV No Yes 5 3 10
Oral cavity I–II Yes No 17 7 28
III–IV Yes No 17 7 28
PET-CT, computed tomography-positron emission tomography.
* Waiting time was incorporated in the model using a beta PERT distribution (see above for the expected, minimum, and maximum values).
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months and a lifetime horizon were used to incorporate most
long-term effects.Progression Free
Local / Regional 
Recurrence
†
†Model Input Parameters
Actual treatment and diagnoses were equal for the different
modalities. The waiting time differed, however, because of
deviating process designs. Input parameters of the model are
presented in Table 2. Data from a pilot study in the studied
organization were used to indicate time gains for each process
ﬂow, and were expressed in the number of working days (5 d/wk).
A time gain of 22 working days could in reality cover 30 days of
waiting time. The most conservative estimation (i.e., shortest
time gain) was used for the NWF. In the Markov model, the
parameter’s uncertainty of waiting time was incorporated by a
beta PERT distribution (Table 1). The differing time gains were
related to the RRs of 1.16 for death, and metastases, and 1.15 for
local/regional recurrence for every month waiting time [4]. There-
fore, each tumor location resulted in different transition proba-
bilities between the deﬁned health states. The RRs for the gained
time were assumed to be linearly related to the amount of time
gained. To obtain the RR associated with 5-day, 17-day, or 22-day
reduction in waiting time, the RR for a month was converted to a
1-day reduction multiplied by the time gain per tumor location: 1
þ (RR for 1 month 1)  12/365.5  time gain. To estimate survival,
local/regional recurrence, and metastases for oropharynx and
larynx tumors, parametric survival models (exponential and
Weibull) were estimated stratiﬁed for tumor site and stage.
Estimates were based on data retrieved from medical ﬁles (period
1965–2012) of 2096 patients with HNC (938 with tumors of the
larynx stage I–II and 620 with stage III–IV, and 83 with tumors of
the oropharynx stage I–II and 455 with stage III–IV) [14]. Hazard
ratios reported by Datema et al. [15] were used to convert
transition probabilities for oropharynx tumors to tumors located
at the hypopharynx and the oral cavity. These RRs were assumed
to be equal for survival, local/regional recurrence, and distant
metastases. Toxicity was assumed to be equal for NWF and RWF.Death  
Distant 
Metastasis
†
Fig. 1 – Markov model with half-year cycle time and a
lifetime span.Effects and Costs
Utility scores were combined with life expectancy to calculate
quality-adjusted life-years (QALYs). Utility scores provide a single
index value for health-related quality of life, ranging from 0
(death) to 1 (optimal health), and were estimated on the basis of
EuroQol ﬁve-dimensional questionnaire [16]. The disutilities for
the health states, local/regional recurrence, and metastases were
assumed to be independent of treatment site and disease stage.Costs were estimated as the costs per health care activity in
the studied organizations in 2013 multiplied by the required
health care activities on the basis of opinions of clinical experts
(Appendix A). Costs that potentially differed between the two
logistical processes were mainly focused on because only these
costs could inﬂuence the incremental cost-effectiveness analysis.
Three dimensions of costs were included in the Markov model:1. Event costs: Costs for all the expected health care activities in
need incurred when the health state of a patient changed (e.g.,
a recurrence).2. Follow-up (health state) costs: All follow-up costs for the ﬁrst 5
years after treatment until the next event. From the sixth year
onward, follow-up costs were assumed to be zero.3. Intervention costs: The intervention cost were partly covered by
the costs associated with the implementation of the redesign
(NWF), which is based on the purchase cost for the endoscope
(Pentax chip-on tip) with unit (estimated at €50,000), and
spread over 1000 patients to be diagnosed (1250–1400 patients
expected in 5 years). The intervention costs also covered the
costs for unnecessary activities, which included the costs for
patients whose biopsy under local anesthesia failed and an
Table 2 – Input parameters of Markov model.
Parameter Estimated value SE/95% CI Distribution Source
Utility score for progression-free state
Larynx, stage I–II 0.84 0.03 Beta [14]
Larynx, stage III–IV 0.86 0.02 Beta [14]
Oropharynx, stage I–II 0.85 0.04 Beta [14]
Oropharynx, stage III–IV 0.85 0.02 Beta [14]
Hypopharynx, stage I–II 0.85 0.04 Beta [14]
Hypopharynx, stage III–IV 0.85 0.02 Beta [14]
Oral cavity, stage I–II 0.9 0.05 Beta [14]
Oral cavity, stage III–IV 0.89 0.02 Beta [14]
Disutility local/regional recurrence, and distant metastasis vs.
progression-free survival
0.13 0.07 Beta [14]
Parameters parametric survival model*
Larynx, stage I–II
Mortality (base) 3.5 0.27 Exponential [12]
Mortality (tumor_site_speciﬁc) 1.77 0.46 Exponential [12]
Mortality (log_scale) 0 0 Exponential [12]
Local/regional recurrence (base) 1.73 0.4 Weibull [12]
Local/regional recurrence (tumor_site_speciﬁc) 0.76 0.31 Weibull [12]
Local/regional recurrence (log_scale) 0.32 0.16 Weibull [12]
Distant metastasis (base) 3.5 0.27 Exponential [12]
Distant metastasis (tumor_site_speciﬁc) -1.77 0.46 Exponential [12]
Distant metastasis (log_scale) 0 0 Exponential [12]
Larynx, stage III–IV [12]
Mortality (base) 1.8 0.14 Exponential [12]
Mortality (tumor_site_speciﬁc) -0.78 0.14 Exponential [12]
Mortality (log_scale) 0 0 Exponential [12]
Local/regional recurrence (base) 2.04 0.26 Weibull [12]
Local/regional recurrence (tumor_site_speciﬁc) -1.01 0.21 Weibull [12]
Local/regional recurrence (log_scale) 0.27 0.07 Weibull [12]
Distant metastasis (base) 1.66 0.13 Exponential [12]
Distant metastasis (tumor_site_speciﬁc) -0.86 0.17 Exponential [12]
Distant metastasis (log_scale) 0 0 Exponential [12]
Oropharynx, stage I–II
Mortality (base) 2.6 0.04 Weibull [12]
Mortality (tumor_site_speciﬁc) -0.19 0.18 Weibull [12]
Mortality (log_scale) -0.09 0.03 Weibull [12]
Local/regional recurrence (base) 2.45 0.05 Weibull [12]
Local/regional recurrence (tumor_site_speciﬁc) 0.11 0.23 Weibull [12]
Local/regional recurrence (log_scale) 0.19 0.03 Weibull [12]
Distant metastasis (base) 2.6 0.04 Weibull [12]
Distant metastasis (tumor_site_speciﬁc) -0.19 0.18 Weibull [12]
Distant metastasis (log_scale) -0.09 0.03 Weibull [12]
Oropharynx, stage III–IV
Mortality (base) 2.02 0.07 Weibull [12]
Mortality (tumor_site_speciﬁc) 0.01 0.11 Weibull [12]
Mortality (log_scale) 0.19 0.04 Weibull [12]
Local/regional recurrence (base) 1.9 0.07 Weibull [12]
Local/regional recurrence (tumor_site_speciﬁc) 0.13 0.13 Weibull [12]
Local/regional recurrence (log_scale) 0.29 0.04 Weibull [12]
Distant metastasis (base) 2.02 0.07 Weibull [12]
Distant metastasis (tumor_site_speciﬁc) 0.01 0.11 Weibull [12]
Distant metastasis (log_scale) 0.19 0.04 Weibull [12]
Hazard ratios
Hypopharynx vs. oropharynx 0.86 0.85–0.87 Lognormal [13]
Oral cavity vs. oropharynx 1.06 1.09–1.03 Lognormal [13]
Relative risks: new workﬂow vs. regular workﬂow
Relative risk for local/regional recurrences when gained
1 mo in treatment delay
0.91 0.78–0.98 Lognormal [4]
continued on next page
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Table 2 – continued
Parameter Estimated value SE/95% CI Distribution Source
Relative risk for distant metastases when gained 1 mo in
treatment delay
0.66 0.26–1.06 Lognormal [4]
Relative risk for death when gained 1 mo in treatment delay 0.9 0.76–0.98 Lognormal [4]
CI, conﬁdence interval; SE, standard error.
Gained waiting time is included as a parameter in the model on the basis of a beta PERT distribution and presented in more detail in Table 1.
* Interpretation parameters parametric survival model: S(t) ¼ survival probability at time t ¼ е–λtα. λ ¼ event rate parameter ¼ (base) þ
(tumor_site_speciﬁc). α ¼ shape parameter indicating the time-dependent deviation ¼ 1/(log_scale).
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They also included the costs for patients who received a
diagnostic PET-CT in radiation therapy position with mask,
but in the end appeared to have no indication for radio-
therapy. Only the costs for the health care activities were
included in this study.
To account for inﬂation rates, future QALYs and costs were
discounted at 1.5% and 4%, respectively [17].
Markov Model Analysis
The life-years, QALYs, and expected total costs were calculated per
tumor site and stage (eight patient groups) for the RWF as well as
the NWF. The incremental cost-effectiveness ratio (ICER) was
calculated by dividing the incremental (NWF minus RWF) costs by
the incremental QALYs. This ICER represented the additional costs
of one QALY when the NWF was implemented for the speciﬁc
tumor site. A treatment is considered cost-effective when the ICER
is below the price a patient (or the society) is willing to pay for an
additional QALY (ceiling ratio). A ceiling ratio of €80,000 was
adopted because this is the informal ceiling ratio for high-burden
diseases in The Netherlands [18]. This means that society is willing
to pay €80,000 for an additional year in perfect health. This ceiling
ratio is relatively high compared with those used in other countries,
for example, £20,000 to £50,000 in the United Kingdom [19]. There-
fore, a more conservative ceiling ratio of €20,000 (used for non-
destructive diseases in The Netherlands) was also considered [18].
Sensitivity Analysis
Probabilistic sensitivity analysis using Monte-Carlo simulation
was performed to account for the uncertainty of the input
parameters in the model [3]. The simulation incorporated 5000
iterations. The results of these simulations were illustrated using
cost-effectiveness acceptability curves.
Extrapolation of Results
Patient outcomes were extrapolated to organizational and
national levels (The Netherlands). The incremental net monetary
beneﬁt (INMB) was multiplied by the number of patients treated.
The INMB is a representation of incremental gains/beneﬁts
(QALYs multiplied by the ceiling ratio) minus incremental costs
[20]. For example, an INMB of €100 means that the total beneﬁt of
the proposed change exceeds the total costs with €100 on the
long run. The INMB on the organizational level presented the
number of patients treated within the studied organization
(based on the annual reports of the two participating organiza-
tions) multiplied by the INMB. This organizational INMB repre-
sented the incremental beneﬁt from the perspective of the health
care payers and did not represent the incremental beneﬁt or cost
for the speciﬁc organization. The INMB extrapolated to the
national level for The Netherlands was calculated by multiplyingthe incidence numbers from the Integral Cancer Centre for the
four included treatment sites [21] and the INMB.Results
Different gains in waiting time were realized for the eight included
patient groups (Table 1). Gains in waiting times varied from 5 days
gained for patients treated for oropharynx and hypopharynx
tumors to 22 days gained for patients treated for larynx tumors.
These gains in waiting time resulted in additional incremental
QALYs varying from 0.13 for patients treated for hypopharynx
tumors to 0.66 for patients treated for stage I and II larynx tumors
(Table 3). The new care process (NWF) cost for patients with
tumors located at the larynx and the oral cavity was less
expensive than the RWF cost, which resulted in negative incre-
mental costs. The 95% conﬁdence interval for incremental costs
showed a cost reduction ranging from €242 to €941 per patient
treated for a larynx tumor and from €187 to €1437 per patient
treated for a oral cavity tumor. Incremental costs for the NWF
regarding oropharynx and hypopharynx tumors were small, vary-
ing from a mean additional cost of €304 to €453 per patient. As a
result, ICERs presented a cost of approximately €2875 to €3777 for
an additional QALY gained for patients with oropharynx tumors
and €2119 to €2909 for patients with hypopharynx tumors (Table 3,
and visualized in Figs. 2 and 3). The NWF was cost-effective for all
studied treatment sites, using either the Dutch informal ceiling
ratio of €80,000 for high-burden diseases or the more conservative
ceiling ratio of €20,000. When using a ceiling ratio of €80,000, the
summation of the individual INMB per treatment site and stage
multiplied by the number of potential patients in the studied
organization (Table 3) resulted in an organizational INMB of €14.1
million for the health care payer if the studied organization would
implement the process redesign for all the patients treated for the
included cancer sites. If the more conservative ceiling ratio of
€20,000 was used, an organizational INMB of €3.6 million was
calculated. Extrapolation to the national level of The Netherlands,
using the Dutch ceiling ratio of €80,000 for high-burden diseases
resulted in a national INMB of €91.5 million for the health care
payer. If the more conservative ceiling ratio of €20,000 was used, a
national INMB of €23.3 million was calculated.Discussion
The NWF was cost-effective for all included patients with HNC.
The NWF dominated the RWF for patients treated for cancer of
the larynx and the oral cavity because of less costs and gained
QALYs. The NWF for patients with hypopharynx and oropharynx
cancers was also cost-effective for both ceiling ratios (€80,000 and
€20,000). When society was willing to pay €2500 for a gained QALY
for patients with hypopharynx cancer, and €3500 for patients with
oropharynx cancer, the NWF was cost-effective. When INMBs
were extrapolated to organizational and national levels, the
Table 3 – Outcomes of Markov model for the new workﬂow versus the regular workﬂow per treatment site and stage.
Outcomes Larynx Oropharynx Hypopharynx Oral cavity
I–II III–IV I–II III–IV I–II III–IV I–II III–IV
Costs NWF Mean 7806 15,739 13,588 16,015 13,377 15,700 5045 20,652
95% CI 7260–8345 15,368–16,531 12,608–15,644 15,686–16,586 12,258–15,822 15,330–16,485 3512–11,542 19,904–21,634
Costs RWF Mean 8445 15,993 13,135 15,562 13,068 15,397 5742 20,846
95% CI 7883–8963 15,664–16,672 12,154–15,227 15,254–16,135 11,938–15,532 15,035–16,216 4070–8438 20,107–21,749
QALYs NWF Mean 9.89 7.01 7.66 5.94 6.92 5.21 9.00 7.09
95% CI 8.93–10.90 6.14–7.99 5.78–9.74 5.13–6.79 4.23–10.26 3.08–7.98 5.69–12.91 4.45–10.18
QALYs RWF Mean 9.22 6.37 7.51 5.80 6.79 5.07 8.45 6.55
95% CI 8.47–9.96 5.71–7.03 5.67–9.57 5.01–6.61 4.14–10.01 2.99–7.81 5.32–12.24 4.06–9.55
Incremental QALYs Mean 0.66 0.65 0.15 0.15 0.13 0.13 0.55 0.54
95% CI 0.10–1.32 0.09–1.31 0.02–0.31 0.03–0.31 0.02–0.30 0.03–0.29 0.09–1.19 0.10–1.16
Incremental costs Mean 639 254 452 453 309 304 697 194
95% CI 941 to 242 768 to 353 165–748 193–745 11–616 36–591 1.437 to 187 666 to 330
ICER €/QALY Dominant Dominant 3090 3064 2300 2267 Dominant Dominant
INMB calculated for a ceiling ratio of €80,000
INMB per patient Mean 53,703 51,916 11,260 11,380 10,430 10,408 44,309 43,782
95% CI 9024–106,627 7994–105,569 1506–2463 1829–24,240 1500–23,359 1660–22,906 7690–95,812 7767–92,909
No. of patients in the organization* 89 89 46 46 22 22 36 36
Organizational INMB 4,779,543 4,620,529 517,973 523,471 229,452 228,973 1,595,137 1,576,153
No. of patients in The Netherlands† 355 355 227 227 113 113 528 528
National INMB 19,064,565 18,430,180 2,556,020 2,583,260 1,178,590 1,176,104 23,395,152 23,116,896
INMB calculated for a ceiling ratio of €20,000
INMB per patient Mean 13,905 13,170 2476 2505 2376 2374 11,600 11,091
95% CI 2801–27,200 2196–26,498 34–5838 88–5741 117–5696 165–5530 2485–24,377 2026–23,432
Organizational INMB 1,237,545 1,172,130 113,896 115,230 52,272 52,228 417,600 399,276
National INMB 4,936,275 4,675,350 562,052 568,635 268,488 268,262 6,124,800 5,856,048
CI, conﬁdence interval; ICER, incremental cost-effectiveness ratio; INMB, incremental net monetary beneﬁt; NWF, new workﬂow; QALY, quality-adjusted life-year; RWF, regular workﬂow.
* The total number of patients per treatment site based on the organizational annual report of 2012. The total equally divided between stages I and II and III and IV.
† Numbers based on incidence numbers of Integral Cancer Centre in The Netherlands in 2012: www.cijfersoverkanker.nl.
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Fig. 2 – (A-H) Cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs) of the redesigns for the treatment
of tumors of the larynx and the oropharynx separated per stages. NWF, new workﬂow; QALYs, quality-adjusted life-years;
RWF, regular workﬂow.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 8 7 – 5 9 6 593beneﬁts of redesigning the workﬂow became very clear. When
the Dutch ceiling ratio of €80,000 for high-burden diseases
was used, an INMB of €14.1 million for the health care payers
was calculated if the redesign would be fully implemented in the
studied organization, and an INMB of €91.5 million if extrapolated
to the national level. Even when the more conservative ceiling
ratio of €20,000 was used, beneﬁts remained obvious. This
extrapolation of results, however, is purely indicative. The
hypothetical extrapolation to the national level is based on the
assumption that the redesign of the relevant processes would
be comparable for all care organizations in The Netherlands.However, the reality is different. Furthermore, the incidence
numbers of the tumor sites, which were used in the model
to extrapolate results, were evenly distributed between stages I
and II and stages III and IV, because the precise distribution
between stages was not available. Therefore, this hypothetical
extrapolation of the INMB serves only as an illustration of
the potential beneﬁts of relatively small logistical process
improvements.
Differences in cost-effectiveness between tumor sites were
partly based on differences in implementation costs between the
two organizational changes. The biopsy under local anesthesia
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Fig. 3 – (A-H) Cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs) of the redesigns for the treatment
of tumors of the hypopharynx and the oral cavity separated per stages. NWF, new workﬂow; QALYs, quality-adjusted life-
years; RWF, regular workﬂow.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 8 7 – 5 9 6594(NWF) was less expensive than the regular biopsy under full
anesthesia (RWF), whereas the NWF regarding the CT-PET process
was more expensive than for the RWF. In addition, the redesigned
biopsy process resulted in larger effects on gained waiting timewhereas the redesign of the CT-PET process resulted in a larger
number of gained QALYs. Because the cost-effectiveness accept-
ability curves presented the NWF for all patient groups as cost-
effective at very small ceiling ratios, no additional one-way
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 8 7 – 5 9 6 595sensitivity analysis was performed to calculate separate contribu-
tions of these uncertain parameters on the outcome.
Some limitations of this study should be discussed. First, the RRs
for decreased waiting times were assumed equal for all eight sites
and stages although these resulted in different transition probabil-
ities between health states. Nevertheless, the effect of a decreased
time to initiation of treatment could be considered more pro-
nounced for faster growing tumors within patients with HNC.
Second, one could question the assumption that the RR for
decreased waiting time is linearly related to time, which directly
affects the outcomes in the model. Third, the RRs used to conﬁgure
the health states transition probabilities of patients with oropharynx
tumors to those with hypopharynx and oral cavity tumors were
assumed equal for survival, local/regional control, and metastases.
This assumption, which could affect the outcomes, might be
inconsistent with reality. Fourth, differences in QALYs between
the NWF and the RWF might be underestimated because shortened
time to treatment might result in smaller radiation treatment ﬁelds
and, therefore, less radiation-related toxicity (improved quality of
life for the NWF). Fifth, time gains from the introduced workﬂow
were based on preliminary results from a pilot study. These might
not represent the time gains that are aimed for because the
organizations are still in a learning process, and might further
improve the process to gain additional time. If waiting time is
expected to further improve, the cost-effectiveness of the NWF is
likely to improve as well. Sixth, the decreased time before patients
were diagnosed could result in reduced stress levels for patients
because living in uncertainty is extremely stressful, especially when
cancer related. The potentially reduced stress level for the NWF was
not included in the outcomes of the model. Seventh, a health care
perspective was used for this model. All societal costs and beneﬁts
regarding the loss of productivity at work were not included.
Incorporating these costs might improve the cost-effectiveness of
the NWF because QALYs were gained, which could result in reduced
loss of productivity. Eighth, because the model was based on the
current existing literature, pilot data, and expert opinions, results
should be carefully interpreted, and best be conﬁrmed by results
from a prospective study. Therefore, the presented results are
mainly indicative regarding the possible beneﬁts of efforts to rede-
sign the care process.
Positive effects of the redesigned processes have to be men-
tioned as well. Patient groups, which were not incorporated in
the outcomes of the model, beneﬁted from the redesign as well.
Because the biopsies of a number of patients were performed
under local anesthesia, the operating room became available for
other patients with HNC. Patients with locally advanced tumors,
who were not included in the trajectory for biopsy under local
anesthesia or who were on the waiting list for surgery, experi-
enced less waiting time before treatment. Another positive effect
of the study was a possibly improved diagnosis and treatment
decision because PET-CT images became available during the
diagnostic process instead of afterwards, and in particular before
the performed biopsy.
Although health care professionals might be less attracted to
process and organizational redesign than to adapting new tech-
nologies, the present study demonstrated that the redesign of a
care process resulted in signiﬁcantly better long-term patient
outcomes and cost savings for particular patient groups. The
reduction in waiting time for treatment is shown to positively
affect patient prognosis [4,6,8]. An additional problem with
process redesign interventions and a more efﬁcient use of
medical technologies is the inappropriate use of ﬁnancial moti-
vators. More efﬁcient use of technologies, and redesigned care
processes, which may result in beneﬁts for the patient, might not
be rewarded by ﬁnances or even result in fewer payments. This is
an important impediment for creating efﬁcient and high-quality
care. To support efﬁcient and qualitative care, organizationsshould be rewarded appropriately by the ﬁnancers of care. This
study proved that the reorganization of care processes can
improve the efﬁciency of care, and reduce waiting times, result-
ing in improved patient outcomes. Therefore, interventions that
aim to improve care by redesigning logistics deserve attention.
The implementation of these redesign interventions on a much
wider scale should be considered.
In conclusion, a redesign intervention of the diagnostic
process and the radiotherapy preparation for patients with HNC
resulted in reduced waiting time for treatment and more QALYs
and proved to be cost-effective.Acknowledgments
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